NASDAQ · MRSN
Mersana Therapeutics, Inc.
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
Loading market information…
NASDAQ · BDSX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biodesix, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biodesix, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:40 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$1.60-14.64% vs estimate |
| $17.96M-7.51% vs estimate |
| Q4 2024 | Mar 3, 2025 | -$1.20-1,614.29% vs estimate | $20.43M+2.79% vs estimate |
|---|
| Q3 2024 | Nov 1, 2024 | -$1.40+4.28% vs estimate | $18.15M-2.24% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $35.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
$2.62-$0.01 (-0.38%)
OnKure Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.3% below the high.
$1.55+$0.03 (+1.97%)
PDS Biotechnology Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$7.77-$0.24 (-3.0%)
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.26% below the high.
$1.60+$0.07 (+4.58%)
INmune Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$5.03-$0.14 (-2.71%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$3.52$0.00 (0.0%)
Wellgistics Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.39% below the high.
$1.31-$0.21 (-13.82%)
Skye Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.89% below the high.
